LBNL scientific analysis spinout Newomics has been backed by Berkeley Catalyst Fund to develop a testing platform initially targeting medical and biotech applications.
Newomics, a US-based scientific analysis technology spinout of Lawrence Berkeley National Laboratory (LBNL), closed an oversubscribed $3.9m series A round today led by VC firm Photon Fund and backed by Berkeley Catalyst Fund.
LBNL is a US government-owned laboratory hosted by University of California (UC) Berkeley, which launched Berkeley Catalyst Fund to support LBNL spinouts as well as those from UC Berkeley and San Francisco.
Founded in 2014, Newomics is developing a testing platform primarily intended for medical and biotech applications.
The technology works by applying liquid chromatography-mass spectrometry, a technique combining physical separation with mass analysis, to minute biospecimens stored on a silicon-microfluidic-chip.
The spinout already supplies a range of multinozzle emitters and is also planning to offer services including proteomic, metabolomic and lipidomic analysis. Other potential applications include environmental, food and forensic testing.
Newomics will use the cash to add to its management team as it looks to complete commercialisation of the emitter and develop assays based on the same approach.
Pan Mao, a former biophysics postdoctoral fellow of LBNL, co-founded Newomics together with the spinout’s CEO, Daojing Wang, previously with LBNL for 11 years as a principal investigator and scientist.
